Candidiasis Therapeutics Market Scope
The candidiasis therapeutics market is expected to grow in the future due to the increase in the number of patients affected by candidiasis infection and an increase in the susceptible immune-compromised patient pool. Candidiasis, also known as common yeast infection, is an infection in the skin caused by candida. High adoption due to innovative drugs will help to boost the global candidiasis therapeutics market.
The market study is being classified, by Application (Multispecialty Hospitals, Cancer Research Institutes and Others) and major geographies with country level break-up.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Candidiasis Therapeutics market throughout the predicted period.
Novartis International AG (Switzerland), Amgen Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Pfizer (United States), Bayer AG (Germany), Merrion Pharmaceuticals Plc. (Ireland), Ablynx (Belgium), Genta Incorporated (United States), Galapagos NV (Belgium), Catena Pharmaceuticals, Inc. (United States) and Medivir (Sweden) are some of the key players profiled in the study.
AdvanceMarketAnalytics has segmented the market of Global Candidiasis Therapeutics market by Type, Application and Region.
On the basis of geography, the market of Candidiasis Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In July 2018, SCYNEXIS, Inc. announced positive results from its Phase 2b, a dose-finding study evaluating oral SCY-078 for the treatment of vulvovaginal candidiasis. SCY-078, the first representative of a novel oral and intravenous triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including VVC, invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections.
25 April 2018, NovaDigm Therapeutics has announced the publication of positive data from a Phase IIa study of its NDV-3A vaccine as a treatment for recurrent vulvovaginal candidiasis.
- Increasing Consumer Inclination towards Maintaining Aesthetic Appearance
- Increase in the Susceptible Immune-compromised Patient Pool
- Growing Awareness for Candidiasis Infection
- High Investment in Healthcare
- Owing Awareness for Candidiasis Infection in Developing Markets
- Competition from Herbal Medicines and Alternate Therapies
- Less R&D Activity in this Sector
Key Target AudienceCandidiasis Therapeutics Manufacturers, Candidiasis Therapeutics Distributors/Traders/Wholesalers, Candidiasis Therapeutics Subcomponent Manufacturers, Industry Association and Downstream Vendors
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase